Previous close | 12.89 |
Open | 12.91 |
Bid | 12.90 x 300 |
Ask | 12.97 x 200 |
Day's range | 12.74 - 13.38 |
52-week range | 10.92 - 59.99 |
Volume | |
Avg. volume | 998,117 |
Market cap | 778.382M |
Beta (5Y monthly) | 0.85 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage Therapeutics said Wednesday its Parkinson's treatment failed in a midstage study, and Sage stock collapsed to a record low.